TNFRSF17 and Miyoshi myopathy: In conclusion, our study demonstrates not only the feasibility but also the most optimal conditions for the generation of BCMA- and CD38-CAR transduced iNKT cells to maximally exploit the therapeutic properties of BCMA- and CD38-CARs iNKT cells in the battle against MM.